Author:
Mauclet Charlotte,Collard Philippe,Ghaye Benoit,Hoton Delphine,Nana Frank Aboubakar
Funder
Universite catholique de Louvain
Cliniques Universitaires Saint-Luc
Fondation Saint Luc
Subject
Cancer Research,Pulmonary and Respiratory Medicine,Oncology
Reference9 articles.
1. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial;Planchard;Lancet Oncol.,2016
2. Osimertinib plus savolitinib in patients with EGFR mutation-positif, MET-amplified non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study;Sequist;Lancet Oncol.,2020
3. ORCHARD: a phase II platform study in patients with advanced NSCLC who have progressed on first-line Osimertinib therapy;Yu;JTO,2019
4. Acquired BRAF V600E mutation as resistant mechanism after treatment with osimertinib;Ho;J. Thorac. Oncol.,2017
5. Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation;Meng;Lung Cancer,2020
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献